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ABSTRACT
Background: Chronic kidney disease (CKD) is a very common pathology in cats, especially in the geriatric age. A proper 
renal diet is considered the current standard of care to enhance patients’ long-term survival and quality of life. However, 
when diet alone is not sufficient, it is necessary to supplement it with specific substances: these are phosphate binders 
and alkalinizing agents. The aim of this study was to evaluate the effectiveness of a feed supplement containing calcium 
carbonate, calcium lactate gluconate, chitosan and sodium bicarbonate in controlling hyperphosphatemia and metabolic 
acidosis in cats with severe CKD (IRIS, International Renal Interest Society, stage 3 and 4).
Materials, Methods & Results: 10 cats (median BW 4.00 (3.20; 5.70) Kg, BCS 3/5 (2.25; 3.75), 11 (8.25;12.00) years) 
fed with a balanced renal diet were included in the study. To be enrolled in the study cats had to be affected by CKD in 
stages 3 or 4 and show hyperphosphatemia. Treatment consisted in oral administration of the product (Renal, Candioli 
Pharma) at 0.2 g/kg/day mixed with the food for 60 days. The animals were evaluated at the beginning of the study and at 
15, 30, 60 days (T0, T15, T30, T60) for: clinical condition, BW, BCS, blood pressure and for routinely hematochemical, 
biochemical and urinary parameters. Owners were asked to assess appetite of the cat, palatability of the supplement, pres-
ence of vomit and/or diarrhoea, general health and vitality. All statistical analyses were performed using SAS software. 
After checking normality data were analyzed using Kruskal-Wallis and Wilcoxon tests. Results are expressed as median 
(interquartile range). For the parameters P (P < 0.0001), iCa (P = 0.0008) and HCO3 (P = 0.0002) there were statistically 
significant differences among times of supplementation (T0, T15, T30, T60). Statistically significant reduction of serum 
phosphorus concentration was obtained through the study (reduction of 59% at T60 vs T0). Also a statistically significant 
increase of bicarbonate was seen (7% from T0 to T60). At T60 was also recorded an increase of ionized calcium level, 
which however was in normal range. For the other laboratory parameters, no statistical difference was recorded. All the 
owners reported a good palatability of the product. The decrease of vomit and diarrhea episodes and the increase of the 
appetite reported were statistically significant (P < 0.05).
Discussion: The restriction of available dietary phosphorus is now recognised as one of the major contributors in slowing 
the disease progression and improving survival rates. Phosphate binders are able to absorb phosphate (P) in the intestine, 
forming insoluble products that are eliminated with the faeces, thus decreasing serum phosphate levels. The phosphate 
binders contained in the product tested in the present trial were chitosan, calcium lactate gluconate and calcium carbonate. 
During the study P decreased significantly from T0 to T60, reaching the target post-treatment plasma P concentration for 
IRIS stage 3 after 30 days. Another important recommendation for CKD treatment is to use alkalinisation therapy if meta-
bolic acidosis is present. The feed supplement tested in this study also contained sodium bicarbonate. In our study, 90% 
of the patients at the inclusion examination had metabolic acidosis. At the end of the study, the median blood bicarbonate 
concentration was in the normal range, thus reaching the IRIS treatment target. The feed supplement tested was therefore 
effective in reducing blood phosphate levels and in increasing blood bicarbonate levels, thus improving the cats’ clinical 
conditions for the duration of the study without any adverse effect.
Keywords: cats, chronic kidney disease, hyperphosphatemia, metabolic acidosis, feed supplement, phosphate binder.
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INTRODUCTION
Chronic kidney disease (CKD) is a very com-
mon pathology in old cats (more than 15 years; [13]), 
and it can even affect the 50% of them [11]. CKD is 
defined as a kidney disease that has been present for 
three months or longer [25]. Dogs and cats with CKD 
are staged according to guidelines developed by the 
International Renal Interest Society (IRIS) [18].
There is general agreement regarding the nu-
tritional management of CKD when overt signs exist, 
which includes measures to reduce signs of uremia and 
to slow down the progression to later stages of disease 
[12]. Based on clinical trial findings, a renal diet is the 
therapeutic intervention most likely to enhance long-
term survival and quality of life for patients with IRIS 
CKD stages 3 and 4; as a consequence, diet should be 
considered as the current standard for care [2,6,15].
When diet alone is not sufficient, CKD cats 
need to have their diet supplemented with phosphate 
binders and alkalinizing agents [26]. The aim of this 
study was to evaluate the effectiveness of a feed supple-
ment containing calcium carbonate, calcium lactate 
gluconate, sodium bicarbonate and chitosan in cats 
with CKD in IRIS stages 3 and 4. Since CKD cats 
often show poor compliance [2], palatability and ease 
of administration of the product were also evaluated. 
MATERIALS AND METHODS
The study was performed at the Veterinary 
Clinic Napolivet, in Naples (Italy). An owners’ writ-
ten consent was obtained and all the samples were 
collected by the same clinician.
Animals
Using the available detailed database of the 
clinic that included history, physical examination, he-
matology, biochemistry, urinalysis, and urine protein/
creatinine ratio of the patients, ten cats were selected. 
Cats were excluded if they were affected by other con-
comitant diseases like acute kidney injury, prerenal or 
postrenal azotemia, genitourinary tract inflammation 
or infection, urinary tract obstruction, chronic heart 
failure, neoplasia, hyperthyroidism, diabetes.
To be enrolled in the study cats had to be af-
fected by CKD in stages 3 or 4 according to the Interna-
tional Renal Interest Society (IRIS) system [18] (serum 
creatinine concentration above the reference value, 2.9 
mg/dL, on at least 2 different consecutive occasions) 
and show clinical signs of polyuria and polydipsia. For 
the enrollment in the study the animals should also have 
hyperphosphatemia, i.e. a plasma phosphate concen-
tration higher than 5 mg/dL (1.6 mmol/L) for cats in 
IRIS stage 3 and higher than 6 mg/dL (1.9 mmol/L) 
for cats in IRIS stage 4. 
All the animals were fed with the same renal 
diet (Royal Canin Renal Feline)1 from at least eight 
weeks before the inclusion in the study. The amounts 
offered were based on the estimated requirements ac-
cording to FEDIAF Nutritional Guidelines [10]. The 
same diet had to be maintained for the entire duration 
of the study. After the enrollment (T0), to the diet was 
added a feed supplement (Renal)2 especially designed 
for cats with CKD (Table 1). The dosage was 0.2 g/kg 
body weight/day divided in two daily administrations 
mixed with the feed. The supplement was given for 
60 days and analysis were performed at 15 (T15), 30 
(T30) and 60 (T60) days.
Blood Sampling
Blood samples were collected from the jugu-
lar vein after an overnight fasting and divided into 
three tubes: a tube without anticoagulant for serum, a 
K3-EDTA anticoagulant tube for entire blood, and a 
heparinized tube for hemogas test. Venous haemogas 
analysis was performed immediately after sampling 
with a standard analytical device (Vet Scan i-STAT 
Handheld Analyser)3 to assess bicarbonate (HCO3) 
and ionized calcium (iCA). For complete blood count. 
(CBC) a standard analytical device (scil Vet ABC™)4 
for the determination was used to evaluate: hematocrit 
(HT), hemoglobin (HG), red blood cells (RBC), white 
blood cells (WBC), neutrophils (N), eosinophils (EO), 
lymphocytes (LYM). For the biochemical analysis an 
automated analyser (Echo)5 was used to obtain creati-
Table 1. Composition of the feed supplement (Renal). 
Analytical constituents %
Crude ash 28
Crude protein 6.5
Crude fiber 1
Potassium 0.02
Calcium 13.68
Phosphorus < 0.01
Sodium 0.3
Data are expressed as % on dry matter.
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nine (CREA), blood urea nitrogen (BUN), phosphorus 
(P), total proteins (TP), albumins (ALB), albumin/
globulin (A/G) ratio, glucose (GLU), alanine transami-
nases (ALT) alanine aminotransferases (AST), alkaline 
phosphatases (ALP), bilirubin (BIL) and cholesterol 
(CHOL) values.
Urine Sampling
Urinary samples were collected by free catch. 
Urinalysis included specific gravity (SG) by refractom-
etry and sediment examination. Urine was centrifuged 
(2 min at 1500 x g) and supernatant was removed and 
stored at +4°C to evaluate urine protein (UP) concen-
tration (pirogallol red method) and creatinine con-
centration (Jaffè method) within 12 h. Urine protein/
creatinine (UPC) ratio was then calculated.
Clinical examinations
During each visit a complete physical examina-
tion was performed and body weight (BW) and body 
condition score (BCS, 1-5 point scale, [28]) were evalu-
ated. Blood pressure (BP) measurements were also 
taken by an indirect Doppler method using the radial 
pulse with the cat in sternal recumbency or sitting. 
At each examination, five measures were performed 
and the mean value was recorded. During each visit a 
questionnaire was given to the owner to assess: appetite 
of the cat, palatability of the supplement, presence of 
vomit and/or diarrhoea, general health and vitality.
Statistical Analysis
The normality of the blood parameters distribu-
tion was checked by a Shapiro Wilks test for normality 
using the PROC UNIVARIATE. Since all distributions 
appeared to be non-normal (P < 0.05), blood param-
eters were compared by the Kruskall Wallis test in 
relation to the time of supplementation, by means of 
PROC NPAR1WAY. If the Kruskall Wallis test result 
was significant, a multiple comparison analysis based 
on pairwise two-sample Wilcoxon comparisons was 
performed (P < 0.05 was considered significant).
RESULTS
All the ten cats selected completed the study. 
Signalment and general characteristics are presented 
in Table 2. The main breed represented was European 
shorthair and all the animals were neutered. 9 cats were 
in IRIS stage 3, only 1 cat was in IRIS stage 4.
Table 2. Signalment data of cats.
Breed
European shorthair 8/10
Persian 2/10
Sex
Spayed female 4/10
Neutered male 6/10
Age (years) 11 (8.25;12)
IRIS stage
3 9/10
4 1/10
Body weight (kg) 4 (3.12; 5,7)
BCS 3 (2.25; 3,75)
Clinical signs
Decreased appetite 9/10
Vomit/diarrhea 8/10
Breed, sex and clinical signs are expressed as number of cats/
total. Age, IRIS stage, body weight, BCS (Body Condition 
Score) are expressed as median (interquartile range).
No statistical differences were recorded for 
ematochemical parameters measured during the study 
(Table 3).
Data on the biochemical profile are presented 
in Table 4. Crea and BUN, markers of renal func-
tion, remained stable and no significant differences 
between day 0 and day 60 were recorded. Statistically 
significant differences were only recorded for P values 
(P < 0.0001) that decreased throughout the study with 
a reduction of 59% at T60 vs T0. 
In Table 5 the hemogas parameters are pre-
sented: both iCa (P = 0.0008) and HCO3 (P = 0.0002) 
showed statistically significant differences among 
times of supplementation (T0, T15, T30, T60). iCa 
level at 60 days was the lowest and significantly dif-
ferent from the other levels (P < 0.05). There were also 
differences among the HCO3 levels at different times: 
the levels at 0 and 15 days differed (P < 0.05) from 
the levels at 30 and 60 days and it was detected a 7% 
increase from T0 to T60.
Urinalysis (Table 6) didn’t show any significant 
change and UPC, UP and SG remained stable until T60. 
Neither for blood pressure measurements significant 
differences were reported (Table 7).
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All the owners reported a good palatability 
of the product that was consumed by all the animals 
during the supplementation. From T15, general health 
improvement was observed; at T0, 80% of the patients 
presented vomit and diarrhea, which were no longer 
reported from T15 (P < 0.05). Furthermore, 90% of the 
cats were anorexic at the first examination. Of these, 
66% showed an increase in appetite during the study 
(P < 0.05). No increase of body weight or body condi-
tion score was observed.
Table 3. Ematochemical parameters measured during the study.
Parameter
Laboratory 
standard 
reference 
range
T0 T15 T30 T60
HT % 26.00-45.00 24.30 (20.35;31.00) 25.55 (21.25;31.225) 25.35 (21.07;32.87) 25.35 (21.57;34.05)
HG g/dl 8.00-15.00 9.95 (8.97;11.17) 10.45 (9.75;11.15) 10.65 (10.15;11.675) 11.3 (9.80;12.45)
RBC 106 mm3 5.00-10.00 5.55 (5.10;6.70) 5.65 (5.25;6.65) 6.05 (5.62;6.75) 6.66 (5.43;6.80)
WBC 103 mm3 5.50-19.00 7.25 (3.85;11.37) 6.65 (4.92;14.1) 8.05 (5.37;11.15) 7.93 (5.22;10.27)
N 103 mm3 2.50-12.00 4.15 (2.34;8.09) 4.60 (2.43;9.43) 4.80 (3.80;7.85) 5.35 (2.57;7.57)
EO 103 mm3 0-1.50 1.00 (0.82;1.23) 1.20 (1.10;1.51) 1.00 (0.575;1.245) 0.95 (0.72;1.17)
LYM 103 mm3 1.50-7.00 1.05 (0.58;1.97) 1.25 (0.66;1.70) 1.05 (0.82;1.65) 1.10 (1.02;1.37)
Data are expressed as median (interquartile range); T: time in days.
Table 4. Biochemical parameters measured during the study.
Parameter
Laboratory 
standard 
reference 
range
T0 T15 T30 T60
BUN mg/dL 20.00-50.00
146.50  
(95.50;214.50)
154.00  
(90.25;191.00)
159.00  
(88.50;188.20)
150.00  
(79.05;195.00)
CREA mg/dL 0.50-2.00 4.00 (3.50;4.55) 4.05 (3.02;4.40) 3.95 (3.02;4.50) 3.75 (3.02;4.42)
P mg/dL 2.70-5.00 8.15 (7.47;8.70) 5.20 (4.50;5.55) 4.65 (4.05;5.02) 3.35 (3.13;3.73)
TP mg/dL 6.00-8.00 6.05 (5.75;6.82) 6.26 (5.87;6.90) 6.45 (6.12;7.03) 6.60 (6.17;7.07)
ALB mg/dL 2.20-3.50 2.75 (2.40;3.19) 2.60 (2.50;3.10) 3.05 (2.55;3.47) 3.14 (2.82;3.37)
A/G mg/dL 0.80-1.30 0.65 (0.52;0.80) 0.70 (0.50;0.80) 0.80 (0.62;0.80) 0.90 (0.82;1.00)
GLU mg/dL 60.00-120.00
105.00  
(87.25;117.75)
105.50  
(98.25;112.00)
103.00  
(98.00;111.25)
96.50 
(91.25;102.75)
ALT UI/L 7.00-40.00 30.50 (25.00;41.25) 33.50 (27.00.5;42) 35.00 (31.25;39.75) 35.50 (31.00;45.00)
AST UI/L 7.00-40.00 34.50 (18.50;43.75) 36.00 (24.00;45.25) 32.50 (18.25;39.00) 33.50 (20.75;38.00)
ALP UI/L 4.00-50.00 58.50 (54.00;67.00) 70.50 (65.25;78.25) 61.00 (54.5;74.00) 63.00 (55.25;85.25)
BIL mg/dL 0-0.50 0.17 (0.12;0.21) 0.20 (0.12;0.22) 0.20 (0.15;0.24) 0.15 (0.14;0.17)
CHOL mg/dL 70.00-150.00
114.00 
(102.50;130.00)
136.50  
(102.25;157.50)
119.00  
(98.75;134.00)
104.50  
(83.00;121.00)
Data are expressed as median (interquartile range); T: time in days.
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Table 5. Hemogas parameters measured during the study.
Parameter
Laboratory 
standard 
reference 
range
T0 T15 T30 T60
HCO3 mmol/L 16.00-24.00 15.70 (15.70;15.87) 16.00 (16.00;16.00) 16.35 (16.05;16.87) 16.85 (16.42;17.00)
iCa mmol/L 1.16-1.30 1.17 (1.15;1.18) 1.21 (1.18;1.22) 1.22 (1.19;1.26) 1.30 (1.26;1.31)
Data are expressed as median (interquartile range); T: time in days.
Table 6. Urinary parameters measured during the study. 
Parameter
Laboratory 
standard 
reference 
range
T0 T15 T30 T60
UPC <0.50 0.55 (0.40;0.69) 0.55  (0.42;0.69) 0.53 (0.41;0.60) 0.65 (0.41;0.74)
UP mg/dL 0-100.00 362.00 (218.00;407.25) 335.00 (203.50;391.25) 298.50 (181.75;349.00)
236.00 
(169.90;268.75)
SG 1020-1040 1015 (1010;1019) 1017 (1015;1022) 1018 (1013;1020) 1025 (1016;1025)
Data are expressed as median (interquartile range); T: time in days.
Table 7. Blood pressure measured during the study.
Parameter
Laboratory 
standard 
reference 
range 
T0 T15 T30 T60
BP mmHg <95/<150
100/165 
(90/148;108/172)
105/160 
(97/150;112/170)
105/160 
(100/150;120/165)
90/140 
(90/140;90/150)
Data are expressed as median (interquartile range); T: time in days.
DISCUSSION
Since in most CKD cases it is not possible to 
treat the underlying cause, treatment goals are to man-
age the metabolic complications in order to improve 
the quality of life and slow CKD progression [8].
Several markers have been associated with 
shorter survival in cats with CKD, including protein-
uria, anaemia, and hyperphosphatemia [4]. In addition, 
both in humans and cats a highly significant association 
between increased plasma phosphate concentration and 
shorter survival time has been reported [20]. 
Phosphate is freely filtered at the glomerulus, 
thus its plasma concentration can be considered as a 
marker of the glomerular filtration rate (GFR) [4]. The 
mechanisms involved in phosphorus homeostasis are 
complicated and still not fully clear [7]. It is known 
that it depends on the balance between dietary intake, 
the exchange of phosphorus between extracellular 
and bone storage pools, and renal excretion [14]. It 
is also closely interlinked with calcium homeostasis, 
since both minerals plasma levels are modulated by 
the calciotropic hormones, PTH and calcitriol, and an 
increase in plasma phosphorus concentration causes a 
reciprocal decrease in ionized calcium concentration 
via the law of mass action [14].
In humans there is evidence that hyperphos-
phatemia is associated with vascular calcification and 
nephrocalcinosis, with a subsequent more rapid disease 
progression [19]. The situation in cats appears to be 
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different. In fact, in the only published work that corre-
lates kidney lesions with clinicopathologic variables in 
cats with naturally occurring CKD, plasma phosphate 
was associated with interstitial fibrosis but was not 
associated with tubular mineralisation [4]. This sug-
gests that hyperphosphatemia in cats may not involve 
parenchymal mineralization but may contribute to renal 
fibrosis with another mechanism, thus leading to CKD 
progression [22]. So far this highlights the need for 
more aggressive control of hyperphosphatemia and re-
nal secondary hyperparathyroidism in cats with CKD.
Therefore, the restriction of available dietary 
phosphorus is now recognised as one of the major 
contributors in slowing the disease progression and 
improving survival rates [2].
IRIS guidelines recommend maintaining plas-
ma phosphate within the target reference range, which 
is different for each CKD stage, by reducing phosphate 
intake via dietary restriction, often in combination with 
a dietary phosphate binder.
In the present study this strategy was effective 
and P level decreased significantly from T0 to T60, 
(its median value diminishing from 8.30 to 3.58 mg/
dL) and reached the target post-treatment plasma P 
concentration for IRIS stage 3 (from 2.7 to 5.0 mg/
dL) after 30 days of administration (median value at 
T30: 4.83 mg/dL).
Phosphate binders are able to absorb phos-
phate in the intestine, forming insoluble products that 
are eliminated with the faeces, thus decreasing serum 
phosphate levels [27].
The phosphate binders in the product tested in 
the present trial were chitosan, calcium lactate gluco-
nate and calcium carbonate.
Chitosan is deacetylated glucosamine made 
from chitin and acetyl glucosamine [23]. Previous stud-
ies in humans and cats with spontaneous CKD showed 
the efficacy of chitosan, alone or in combination with 
calcium carbonate, to control hyperphosphatemia and 
reduce azotemia [2,29,30].
Calcium lactate gluconate is a calcium salt and 
it has been used as a gut phosphate binder in human 
medicine, in association with calcium carbonate [9]. 
Calcium carbonate is widely used both in human and 
veterinary medicine, because of its availability, ease 
of use and its low cost compared to other binders [16]. 
In human medicine it has been hypothesized 
that in addition to binding dietary phosphate, calcium 
carbonate prevents or even reverses a negative skeletal 
calcium balance, thus decreasing fracture risk, which 
is typical of CKD [16]. 
The use of calcium-based phosphorus binders has 
the recognised side effect of increasing the risk of hyper-
calcemia in human medicine [27], although little data is 
available in veterinary medicine [7], especially in cats. 
In the present study, the serum ionized calcium 
levels of the patients were significantly higher at T60 
than at T0, but never increased beyond the reference 
range (1.1-1.4 mmol/L [24]). In any case, the possible 
risk of hypercalcemia is the reason why it is important 
to check the plasma calcium concentration (preferably 
the ionised fraction), when monitoring a patient on a 
phosphate-restriction regimen using calcium-based 
phosphorus binders [7,26].
Another important recommendation for CKD 
treatment is to promote alkalinisation if metabolic aci-
dosis is present [17]. It has been reported that metabolic 
acidosis affects 15% of cats in IRIS Stage 3, and more 
than 50% of cats in IRIS Stage 4 [21]. 
Patient’s acid-base status should therefore be 
checked, if possible using blood gas analysis, and on 
the base of the laboratory findings metabolic acidosis 
should be treated [25].
IRIS provides guidelines for metabolic acido-
sis treatment in Stage 2-4 CKD cats. If this condition 
is confirmed (blood bicarbonate or total CO2 < 16 
mmol/L) sodium bicarbonate needs to be orally ad-
ministered to maintain blood bicarbonate or total CO2 
in the range of 16-24 mmol/L.
The feed supplement tested in this study also 
contained sodium bicarbonate.
In our study, 90% of the patients at the inclu-
sion examination had a blood bicarbonate concentra-
tion under the normal range (16-24 mmol/L). At the 
end of the study, the blood bicarbonate concentration of 
all the patients was in the normal range, thus reaching 
the IRIS treatment target.
In human patients with CKD, chronic meta-
bolic acidosis has been associated with an alteration 
in bone metabolism, insulin resistance, protein-energy 
wasting and accelerated progression of kidney disease. 
A low serum bicarbonate level has also been associated 
with high mortality in human beings [5]. Consequently, 
bicarbonate supplementation has been proposed as a 
renoprotective strategy [1]. Evidence from clinical 
trials suggests that alkali therapy could retard the pro-
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gression of CKD [5]. To the authors’ knowledge, no 
previous studies have been performed in cats to evalu-
ate the nephroprotective property of sodium bicarbon-
ate, and further investigations are needed.
Cats in general, and more specifically cats with 
CKD, are known to have problems with their appetite 
[2]. It has also been reported that the addition of a 
phosphorus binder may reduce food intake in azotemic 
cats [3]. This effect was not seen in the present study, 
and 66% of the patients showed an increase in appetite, 
probably due to the improving clinical conditions.
Although the present study has yielded some 
findings, its design is not without flaws. They include 
the low number of cats in the trial and the lack of a 
control group. Even the duration of the clinical trial 
could also be considered a limitation, because CKD 
therapies should continue for long term periods. 
CONCLUSIONS
Additional researches are required, but even 
with the above-mentioned limitations, we can con-
clude that when a balanced diet specifically designed 
for cats with CKD is not sufficient to improve meta-
bolic status of the subjects a specific supplementation 
is required. The supplement tested was effective in 
reducing blood phosphate levels and in increasing 
blood bicarbonate levels, thus improving the cats’ 
clinical conditions for the duration of the study with-
out any adverse effect.
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